Shares of Compass Pathways (CMPS) fell markedly during afternoon trading, sliding 9.3% to $11.83 from recent peaks. The retreat took the stock back from a 52-week high of $14.76 that had been established following a sustained rally tied to a string of positive corporate developments over recent weeks.
There was no fresh company-specific announcement to explain the selloff. Instead, the decline coincided with a broader pullback across high-beta biotech names as the market shifted into a risk-off posture. Investors appear to be trimming exposure ahead of a potentially binary clinical event - the COMP006 Phase 3 26-week Part B durability data readout, which is expected in early Q3 2026. That dataset will address durability of effect following two initial doses, and its binary nature creates pronounced upside and downside risk for the shares.
The wider U.S. equity market provided little support. At the same time as CMPS was moving lower, the S&P 500 declined 2.2%, the Dow Jones Industrial Average fell 1.0%, and the NASDAQ dropped 3.8%, generating a broad negative backdrop that typically amplifies moves in pre-revenue, high-beta biotech stocks.
Analyst commentary has highlighted potential commercial upside while acknowledging market uncertainties. Jefferies noted that COMP360 could exceed 2027 consensus revenue estimates of $60 million, drawing a parallel with Johnson & Johnson’s Spravato, an intranasal esketamine product that generates roughly $2 billion in annual sales. Jefferies’ view referenced Spravato’s distribution scale, which expanded to over 7,500 administration sites from about 4,000 in 2025, while treating fewer than 100,000 U.S. patients against a total addressable market estimated to exceed 4 million patients.
Clinical context is central to the valuation discussion. Phase 3 studies 006 and 005 previously met their primary endpoint at Week 6, demonstrating a -3.6 to -3.8 point difference versus placebo or 1 mg COMP360 on the Montgomery-Åsberg Depression Rating Scale. The forthcoming 26-week data from Study 006 is intended to shed light on how durable that efficacy is after two upfront doses.
Jefferies’ analysis also outlined how COMP360 might be used and billed if approved. The prospective label could allow one to two initial doses followed by episodic retreatment of two to four additional doses per year. That contrasts with Spravato’s potential for up to 56 doses annually. The treatment-resistant depression label being sought would cover both monotherapy and adjunct therapy uses, and pricing for COMP360 is expected to be competitive with Spravato’s range of $30,000 to $70,000.
Taken together, several forces appear to have converged to push CMPS lower on the session. The lack of a fresh catalyst, the stock’s proximity to multi-year highs, the upcoming binary clinical data, and a sharply negative macro environment have combined to produce the selloff. At present, the pullback reads as technical consolidation rather than evidence of any deterioration in Compass Pathways’ regulatory or clinical trajectory.
For market participants focused on sectors and risk exposures, this episode highlights the sensitivity of pre-revenue biotechs to broad market swings and event-driven clinical risk. The immediate performance impact is concentrated in the biotech sector, but the move also reflects wider equity market dynamics that affected major indices during the trading session.